A replicating RNA vaccine, formulated with a lipid-based nanoparticle emulsion, produces antibodies against the COVID-19 coronavirus in mice and primates with a single immunization. These antibodies potently neutralize the virus in young and old animals. The antibody levels induced are comparable to those in recovered COVID-19 patients. This formulation is shelf-stable, with mass-production and distribution advantages.